Vectofusin-1 

Vectofusin-1 is a histidine-rich cationic amphipathic peptide derived from the LAH4 (HY-P0311) peptide family, and also acts as a Viral entry enhancer. Vectofusin-1 promotes the adhesion and fusion of retroviral/lentiviral vectors with cell membranes during viral entry, thereby improving transduction efficiency. Vectofusin-1 potently enhances lentiviral transduction of cells^[1][2].

Vectofusin-1 (12 μg/mL; 6 h) potently enhances the transduction efficiency of multiple lentiviral and retroviral pseudotypes in umbilical cord blood-derived hCD34⁺ hematopoietic stem/progenitor cells, resulting in a GFP⁺ cell proportion ranging from 57.5% to 79.4%, with no detectable cytotoxicity^[1].
Vectofusin-1 (0-35 μg/mL; 5 days) enhances the transduction efficiency of GALVTR-LV in umbilical cord blood-derived hCD34⁺ hematopoietic stem/progenitor cells, with an EC₅₀ of 6 μg/mL and a maximum average transduction efficiency of up to 67%^[1].
Vectofusin-1 (0-100 μg/mL; overnight) has a median toxic concentration (TC₅₀) of 60 μg/mL against umbilical cord blood-derived hCD34⁺ hematopoietic stem/progenitor cells, resulting in a 1-log safety index (TC₅₀/EC₅₀ = 10)^[1].
Vectofusin-1 (12 μg/mL) effectively enhances the transduction efficiency of VSV-G-pseudotyped lentiviral vectors in umbilical cord blood-derived hCD34⁺ hematopoietic stem and progenitor cells (HSPCs), with the proportion of GFP-positive cells ranging from 76.2% to 82.7% in both total cell and subset analyses, which is comparable to the efficacy of Retronectin^[2].
Vectofusin-1 (12 μg/mL) effectively enhances the transduction efficiency of VSV-G-pseudotyped lentiviral vectors in bone marrow-derived hCD34⁺ hematopoietic stem and progenitor cells (HSPCs); in analyses of total cells and subpopulations, the proportion of GFP-positive cells ranges from 69.8% to 74.8%, with a mean vector copy number (VCN) of 6.0 per cell, which is comparable to the efficacy of Retronectin^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Vectofusin-1 (12 μg/mL; ex vivo; 6-hour treatment) exhibits no deleterious effects on the transduction, viability, differentiation, or sustained engraftment of human hCD34⁺ cells in BALB-Rag/γC mice, supporting a safe profile for ex vivo HSC transduction applications^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2778.48

C₁₃₂H₂₂₉N₃₉O₂₆

Solid

White to off-white

Lys-Lys-Ala-Leu-Leu-His-Ala-Ala-Leu-Ala-His-Leu-Leu-Ala-Leu-Ala-His-His-Leu-Leu-Ala-Leu-Leu-Lys-Lys-Ala-NH2

KKALLHAALAHLLALAHHLLALLKKA-NH2

Room temperature in continental US; may vary elsewhere.

Sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

• [1]. Fenard D, et al. Vectofusin-1, a new viral entry enhancer, strongly promotes lentiviral transduction of human hematopoietic stem cells. Mol Ther Nucleic Acids. 2013;2(5):e90. Published 2013 May 7.

  [2]. Piovan C, et al. Vectofusin-1 Promotes RD114-TR-Pseudotyped Lentiviral Vector Transduction of Human HSPCs and T Lymphocytes. Mol Ther Methods Clin Dev. 2017;5:22-30. Published 2017 Mar 8.